“Please welcome Claudia to the stage; she will be discussing resistance mechanisms to immune checkpoint inhibitors.”
If you look at attendance, COVID-19 didn’t derail ASCO20.
In a first nationwide study of its kind, two researchers at Memorial Sloan Kettering Cancer Center, Anna Lee and Fumiko Chino, set out to answer two questions:
It is not a matter of editorial opinion to say these words: Black Lives Matter.
The past ten days have seen an outpouring of emotions as American society, devastated by the tragic murder of George Floyd by four Minneapolis police officers, plunges into a crisis of conscience.
I am almost certain that no other director of an NCI-designated cancer center can claim the distinction of having had a gun pulled on them by police.
FDA has approved Opdivo and Yervoy (nivolumab + ipilimumab) in combination with two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
Brigatinib (Alunbrig) has received FDA approval for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
CLR 131 was granted FDA Fast Track Designation in lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia in patients having received two prior treatment regimens or more.
Computer scientists working with pathologists have trained an artificial intelligence tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment—part of Cancer Research UK's landmark TRACERx study.
